GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (STU:6Y4) » Definitions » Stock Based Compensation

Vicore Pharma Holding AB (STU:6Y4) Stock Based Compensation : €0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vicore Pharma Holding AB Stock Based Compensation?

Vicore Pharma Holding AB's Stock Based Compensation for the three months ended in Sep. 2024 was €0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.


Vicore Pharma Holding AB Stock Based Compensation Historical Data

The historical data trend for Vicore Pharma Holding AB's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Stock Based Compensation Chart

Vicore Pharma Holding AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vicore Pharma Holding AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Vicore Pharma Holding AB Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.


Vicore Pharma Holding AB Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicore Pharma Holding AB Business Description

Traded in Other Exchanges
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines